Utrecht, The Netherlands, June 6, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th, 2022 at 8:00 AM ET. About AM-Pharma AM-Pharma’s purpose […]
Decision from the first pre-specified futility analysis at 400 patients is expected in July Utrecht, The Netherlands, April 25, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study. […]
Utrecht, The Netherlands, March 22, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, are scheduled to participate in SVB Leerink’s Biopharma Private Company Connect on Tuesday, March 29th, 2022. The company will be […]
The lead investigator will present an overview of AM-Pharma’s ongoing Phase 3 REVIVAL study at 11:30 AM PT (2:30 PM ET) on Thursday, March 10, 2022; and New data underscoring the correlation between acute kidney injury severity and patient outcomes following cardiac surgery will be presented in a poster session today San Diego, California and […]
UTRECHT, The Netherlands – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that members of its senior management team are scheduled to participate in the following investor conferences: Cowen 42nd Annual Healthcare Conference on Wednesday, March 9, 2022. The Company will be conducting investor meetings, which can be […]
Utrecht, The Netherlands, January 26, 2022 – AM Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that its Chief Operating Officer, Juliane Bernholz, PhD, is among the authors of a recently published peer-reviewed article discussing the design and implementation of clinical trials for Acute Kidney Injury (AKI). With representation […]
Utrecht, The Netherlands, January 5, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, the Company’s Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, will participate in the following investor conferences: Kempen’s 40th Annual Life Sciences Virtual Crossover Conference on Thursday, January […]
AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million. Kyowa Kirin gains exclusive rights to develop and commercialize ilofotase alfa in […]
Utrecht, The Netherlands, 1 July 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the enrollment of the first patient in Japan as part of its ongoing global pivotal Phase III trial, called REVIVAL. The REVIVAL study is evaluating ilofotase alfa, the Company’s proprietary recombinant human alkaline phosphatase, for the treatment of […]
Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to be used for the 1,400-patient international pivotal Phase III trial of recombinant human Alkaline Phosphatase (recAP) in patients with sepsis-associated acute kidney injury (SA-AKI) AKI […]
